This article is a correction to:
Corrigendum:Research progress of CD80 in the development of immunotherapy drugs
Lanying Li
Lei Yang
DePeng Jiang- Department of Respiratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
A Corrigendum on
Research progress of CD80 in the development of immunotherapy drugs
By Li L, Yang L and Jiang D (2024) Front. Immunol. 15:1496992. doi: 10.3389/fimmu.2024.1496992
In the published article, there was an error in the affiliations. Instead of “Institute of Cancer, Xinqiao Hospital, Army Medical University, Chongqing, China”, all authors should only be affiliated to “Department of Respiratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China”.
In the published article, there was also an error to the Funding section and “Application of single cell biomolecular analysis in the pathogenesis of lung cancer (cstc2022yejh-bgzxm0051)” was accidently omitted.
The corrected funding appears below:
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was supported by The First batch of key Disciplines On Public Health in Chongqing and the Application of single cell biomolecular analysis in the pathogenesis of lung cancer (cstc2022yejh-bgzxm0051).
The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: CD80, immunotherapy drugs, T cells, tumor, autoimmune diseases
Citation: Li L, Yang L and Jiang D (2024) Corrigendum: Research progress of CD80 in the development of immunotherapy drugs. Front. Immunol. 15:1538349. doi: 10.3389/fimmu.2024.1538349
Received: 02 December 2024; Accepted: 03 December 2024;
Published: 18 December 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Li, Yang and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: DePeng Jiang, Z2RwMTE2QGhvc3BpdGFsLmNxbXUuZWR1LmNu
†These authors share first authorship